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Abstract 24 
Quinoxaline 1,4-di-N-oxide (QdNO) and N-acylhydrazone subunit are considered 25 
privileged scaffolds in medicinal chemistry due to its wide spectrum of biological 26 
activities, such as antibacterial, antitubercular, antiviral, anticancer and antifungal. 27 
Beirut’s reaction is the mostly commonly employed synthetic method to obtain QdNO; 28 
however, extended time, low yields and byproducts formation are commonly features 29 
observed during the synthesis. Microwave-assisted organic synthesis (MW) has gained 30 
popularity as an effective way to speed up chemical reactions, increasing yields and 31 
selectivity of a variety of reactions. Therefore, in an effort to synthesize compounds with 32 
potential to tuberculosis treatment, we reported herein the use of MW as a tool to obtain 33 
new QdNO derivatives containing the N-acylhydrazone subunit. Four different synthetic 34 
routes were evaluated by using different benzofuroxan derivatives in the Beirut’s 35 
reaction. The synthetic route D, which employed a dioxolan-benzofuroxan derivative, has 36 
showed to be the best condition to obtain the desired hybrid quinoxaline. MW drastically 37 
reduces the reaction time to obtain all compounds compared to conventional heating. For 38 
compound 13, for example, the use of MW instead of conventional heating was able to 39 
reduce the reaction time in 192-fold. In conclusion, the use of a benzofuroxan derivative 40 
without additional electrophilic sites besides N-oxide nitrogen and the employment of the 41 
microwave-assisted synthesis have proved to be the optimum condition to obtain 42 
quinoxaline 1,4-di-N-oxide N-acylhydrazone derivatives. 43 
 44 
Keywords: quinoxaline 1,4-di-N-oxide, N-acylhydrazone, Beirut reaction, microwave-45 
assisted synthesis, tuberculosis. 46  47 
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INTRODUCTION 48 
Quinoxaline 1,4-di-N-oxide (QdNO) represents an important class of N-oxide compounds 49 
with a wide range of biological activities, such as, antibacterial, antitubercular, antiviral, 50 
anticancer, antifungal and anthelmintic [1]. The wide spectrum of biological activities of 51 
QdNO derivatives has been associated to its ability to generate reactive oxygen species 52 
(ROS) after biotransformation under hypoxic conditions, leading to DNA damage [2–4]. 53 
The antitubercular activity of QdNO derivatives have been described in several papers 54 
published by our research group [5–9], reinforcing the potential of this scaffold to be 55 
used during the design of new antitubercular compounds. 56 
 From a phenotypic-based screening against Mycobacterium tuberculosis (MTB) 57 
containing more than five thousand compounds of our current library, we have identified 58 
the compound 3-cyano-6-methyl-2-phenylquinoxaline 1,4-dioxide 2 (MIC90 = 0.7 μM) in 59 
a series of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives [10] as a 60 
promising scaffold for molecular modifications. Furthermore, we also have reported a 61 
series of quinoxaline 1,4-di-N-oxide derivatives containing the N-acylhydrazone subunit 62 
with potent antitubercular activity. The compound (E)-6-chloro-3-((2-63 
isonicotinoylhydrazono)methyl)-2-methylquinoxaline 1,4-dioxide 1 showed MIC90 value 64 
of 1.6 μM against Mycobacterium tuberculosis H37Rv strain and IC50 value of 55 μM 65 
against VERO cell lines [11]. N-acylhydrazone (NAH) subunit also represents an 66 
important scaffold in the medicinal chemistry due to its wide spectrum of biological 67 
activities [12–15]. Several NAH derivatives has been described with potent antitubercular 68 
activity against MTB H37Rv and multi-drug resistant strains [16,17,14]. Thus, we have 69 
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selected these two compounds (1 and 2) to design a novel quinoxaline hybrid derivative 3 70 
(Scheme 1). 71 
 72 
Scheme 1. Design of the hybrid quinoxaline N-acylhydrazone derivative. 73 
 74 
 75 
The most commonly employed method in the synthesis of QdNO is through the Beirut 76 
reaction, which involves the cycloaddition between benzofuroxan with enamines, α,β-77 
unsaturated ketones, 1,3-dinitriles or enolates leading to formation of quinoxaline-1,4-di-78 
N-oxide [18–21]. Nonetheless, low yields, extended time and non-reaction are commonly 79 
features observed during the synthesis of several QdNO derivatives [8,22].  80 
Microwave-assisted organic synthesis (MW) has gained notoriety as an effective way to 81 
speed up chemical reactions, increase yields and selectivity in a wide range of reactions 82 
[23]. Therefore, in a continuing effort to develop new drug candidates to treat 83 
tuberculosis infection, we report herein the synthesis of a quinoxaline 1,4-di-N-oxide N-84 
acylhydrazone derivative 3 (Scheme 1) exploiting the conventional and the microwave-85 
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assisted synthesis. Furthermore, we also described a comparative study using different 86 
benzofuroxan derivatives in order to optimize the synthetic conditions for obtaining these 87 
hybrid compounds. 88 
 89 
RESULTS AND DISCUSSION 90 
We have evaluated the use of four different benzofuroxan derivatives using conventional 91 
and microwave-assisted synthesis in order to outline a comparative between these two 92 
synthetic methodologies and the best benzofuroxan derivative to obtain the desired 93 
hybrid quinoxaline. The aldehyde-benzofuroxan derivative 6 (Synthetic Route B) was 94 
obtained from 4-chloro-3-nitrobenzaldehyde 4 as previously described [24]. Next, we 95 
obtained the benzofuroxan-N-acylhydrazone derivative 8 from compound 6 (Synthetic 96 
Route A) as already reported [15] and the dioxolan-benzofuroxan 9 (Synthetic Route D) 97 
through an aldehyde protection reaction. The 6-methylbenzo[c][1,2,5]oxadiazole 1-oxide 98 
7 (Synthetic Route C) was purchased commercially (Scheme 2). Moreover, we have used 99 
different catalysts and solvents in both methodologies (conventional and MW), 100 
considering the different reaction conditions that microwave-assisted synthesis requires 101 
[25,26].  102 
 103 
 104 
 105 
 106 
 107 
 108 
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 109 
Scheme 2. Synthetic methodologies to obtain the different benzofuroxan derivatives. 110 
 111 
 112 
Synthetic Route A 113 
A benzofuroxan derivative 8 already containing the N-acylhydrazone subunit was used in 114 
this synthetic route. In the synthetic design, we selected this benzofuroxan derivative due 115 
to the few steps involved in this route (Scheme 3). The only synthetic step was the Beirut 116 
reaction between compound 8 and benzoylacetonitrile 10, which would lead to formation 117 
of the hybrid quinoxaline 3. However, when we tried to perform this reaction, we did not 118 
get the desired product using both methodologies (conventional and MW). A complex 119 
black-oil mixture was obtained with several byproducts and overlapped retention factors 120 
(Rf) in the thin layer chromatography (TLC), becoming it difficult to identification and 121 
separation the desired compound. 122 
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 123 
Scheme 3. General procedure for synthetic route A. 124 
 125 
 126 
Synthetic Route B 127 
After the failure of synthetic route A, a second alternative was planned. In the synthetic 128 
route B, the Beirut reaction was carried out between a benzofuroxan derivative 6 129 
containing an aldehyde function at position 6 and benzoylacetonitrile 10, which would 130 
lead the formation of intermediate quinoxaline 11. Next, compound 11 would be reacted 131 
with isonicotinohydrazide in order to obtain the hybrid quinoxaline 3 (Scheme 4). Once 132 
again, the Beirut reaction generated an even more complex black-oil mixture than the 133 
previous synthetic route. At this point, we realized that a more selective synthetic route 134 
and the use of a benzofuroxan derivative with less electrophilic sites would be necessary. 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
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Scheme 4. General procedure for synthetic route B. 143 
 144 
 145 
Synthetic Route C 146 
Therefore, the synthetic route C was designed in order to improve the selectivity of 147 
Beirut reaction. A benzofuroxan derivative 7 containing a methyl group at position 6 148 
(Scheme 5) was selected for the Beirut reaction with benzoylacetonitrile 10 leading the 149 
formation of the intermediate methyl-quinoxaline derivative 12, which would be 150 
subsequently oxidized to an aldehyde-quinoxaline 11 [11]. The last step would involve 151 
the condensation reaction with isonicotinohydrazide leading the formation of the hybrid 152 
quinoxaline 3. The first step was successfully achieved and the methyl-quinoxaline was 153 
obtained with moderate yields using conventional and microwave-assisted 154 
methodologies, 28% and 35%, respectively. Following the synthetic methodology, the 155 
next step would be performed through an oxidation reaction of the methyl group to 156 
aldehyde using selenium dioxide [27]. However, despite the selenium dioxide be one of 157 
the most used oxidizing agents in the oxidation of methyl groups to aldehydes, this 158 
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reaction did not occurred. Even after a extend reaction time in both methods (MW and 159 
conventional), the TLC only showed the starting reactants and no change was observed in 160 
the reaction medium. The failure of this reaction forced us to plan a new synthetic route 161 
to obtain the desired quinoxaline. 162 
 163 
Scheme 5. General procedure for synthetic route C. 164 
 165 
 166 
Synthetic Route D 167 
Considering the issues involved in synthetic route A - C, a benzofuroxan derivative 168 
without additional electrophilic sites besides the N-oxide nitrogen was selected for 169 
synthetic route D. The dioxolan-benzofuroxan derivative 9 was exploited because the 170 
aldehyde group remains protected by a cyclic acetal during the Beirut reaction (Scheme 171 
6). The first reaction step was the protection of the aldehyde group using ethylene glycol 172 
and acid catalysis leading the formation of the dioxolan-benzofuroxan 9 with good yield 173 
(85%) [28]. Next, the dioxolan-benzofuroxan 9 was reacted with benzoylacetonitrile 10 174 
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through the Beirut reaction in order to generate the dioxolan-quinoxaline 13. This step 175 
was successfully in achieve the desired compound with moderate yields (30%) in both 176 
methods (MW and conventional). Finally, the deprotection reaction was carried out using 177 
acid catalysis and the condensation reaction with isonicotinohydrazide was performed in 178 
situ without further purification of the aldehyde, leading the formation of the hybrid 179 
quinoxaline 1,4-di-N-oxide-N-acylhydrazone derivative 3 with good yield (66%).  180 
 181 
Scheme 6. General procedure for synthetic route D. 182 
 183 
 184 
Synthetic Conditions 185 
Our research group previously evaluated the use of several bases as catalysts and solvents 186 
in Beirut reaction, therefore, wide ranges of synthetic conditions were described for 187 
quinoxaline 1,4-di-N-oxide synthesis. For instance, the preparation of 2-(carboethoxy)-3-188 
phenyl- quinoxaline 1,4-dioxide was achieved with good yields and short reaction time 189 
by using potassium carbonate (K2CO3) in acetone or potassium fluoride on alumina 190 
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(KF/Al2O3) in the absence of an organic solvent [29]. Moreno and coworkers also 191 
demonstrated the synthesis of a series of 1,4-di-N-oxide-quinoxaline-2-carboxylic acid 192 
aryl amide derivatives using ethanolamine as catalyst and methanol as solvent in a 193 
reaction time ranging from 1 to 48 h based on the benzofuroxan used [8]. On the other 194 
hand, some reaction conditions have led to quinoxaline derivatives with low yields [7,22] 195 
and others have required longer reaction times [30]. We also have reported the potential 196 
of the microwave-assisted synthesis to obtain QdNO derivatives in very short reaction 197 
times. For instance, a series of 2-(4-fluorobenzoyl)-3-(trifluoromethyl)quinoxaline 1,4-198 
dioxide was obtained in 15 minutes using microwave irradiation [31].    199 
Therefore, it was necessary the use of different conditions due to previous trials in order 200 
to define the optimum solvent and basic catalysis conditions for each method of synthesis 201 
(conventional and MW). Thus, the conventional heating synthesis was carried out using 202 
dichloromethane as solvent [32] and K2CO3 as catalyst [29] whereas triethylamine and 203 
toluene were used in the microwave-assisted synthesis methodology [11,32]. 204 
Although the synthetic route C has not been able to lead the formation of the hybrid 205 
quinoxaline-N-acylhydrazone, this route was capable to generate an intermediate 206 
quinoxaline in both synthetic methods. By the other hand, the synthetic route D was 207 
successfully to obtain the final desired quinoxaline. It is noteworthy that the microwave-208 
assisted synthesis was outstanding useful to reduce the reaction time and formation of 209 
byproducts when compared to conventional method. For instance, in the synthetic route 210 
C, the reaction time in conventional methodology was carried out during 48 hours with 211 
12% of yield for compound 12, which was obtained in 10 minutes with 26% of yield 212 
through the microwave-assisted methodology (Table 1). A similar result was observed in 213 
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the synthetic route D, in which compound 13 was obtained in 30 minutes with 30% of 214 
yield using microwave-assisted synthesis. Nevertheless, this compound 13 was achieved 215 
with an extremely extended reaction time of 96 hours and several byproducts in the 216 
conventional methodology; however, the yield remained in about 30% (Table 1). 217 
We also evaluated the increase of temperature in all synthetic routes. Temperature above 218 
40 ºC led to an increase in formation of byproducts in both synthetic methods. Regarding 219 
synthetic route A and B, we also carried out both methods at room temperature in order 220 
to evaluate whether the byproducts formation would be reduced, however, the same 221 
complex black-oil mixture was observed.  222 
 223 
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Table 1 Different conditions for the synthesis of 3-aryl-quinoxaline-2-carbonitrile 1,4-di-N-oxide derivative 3 using conventional and 224 
microwave-assisted synthesis. 225 
 226 
 227 
 228 
 229 
 230 
Synthetic 
Method 
Synthetic 
Route 
Catalyst Solvent 
Temperature 
(ºC) 
Time 
MW 
Potency 
(W) 
MW 
Pressure 
(psi) 
Yield (%) 
Conventional 
A K2CO3 CHCl3 40 48 h - - Not obtained 
B K2CO3 CHCl3 40 48 h - - Not obtained 
C K2CO3 CHCl3 40 48 h - - 12 
D K2CO3 CHCl3 40 96 h - - 30 
Microwave 
A triethylamine toluene 40 30 min 70 20 Not obtained 
B triethylamine toluene 40 30 min 70 20 Not obtained 
C triethylamine toluene 40 10 min 70 20 26 
D triethylamine toluene 40 30 min 70 20 30 
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CONCLUSIONS 231 
In conclusion, we highlighted the microwave-assisted synthesis as a tool that can speed 232 
up the synthesis of quinoxaline 1,4-di-N-oxide derivatives through drastic reduction in 233 
reaction time, fewer byproducts formation due to increased selectivity and higher yields. 234 
Specifically for the synthesis of QdNO-N-acylhydrazones derivatives, the use of 235 
benzofuroxan derivatives without electrophilic sites besides the N-oxide nitrogen has an 236 
important role in the Beirut reaction in order to avoid byproducts formation. Four 237 
synthetic methods were tested and different benzofuroxan derivatives were employed. 238 
The reaction, which was performed using benzofuroxan derivatives with an aldehyde or 239 
an N-acylhydrazone subunit, had not successful in obtaining the final compound. By the 240 
other hand, the reaction that was carried out using a dioxolan-benzofuroxan derivative 241 
and microwave-assisted synthesis resulted in the formation of the desired hybrid 242 
compound with good yield (66%) and short reaction time (30 min). 243 
 244 
EXPERIMENTAL 245 
Microwave-organic synthesis was carried out in a Microwave synthesizer Discover SP 246 
(CEM Corporation®). Melting points (mp) were measured using a Mettler FP82+FP80 247 
apparatus (Greifense, Switzerland). Infrared spectroscopy (KBr disc) were performed on 248 
a Nicolet Nexu FTIR Thermo® spectrometer, and the frequencies are expressed in cm-1. 249 
Elemental analyses (C, H and N) were performed on a Perkin-Elmer model 2400 analyzer 250 
and the data were within ± 0.4% of the theoretical values. The NMR for 1H and 13C of all 251 
compounds were recorded on a Bruker 400 UltrashieldTM 13C/1H (400-MHz) NMR 252 
spectrometer using deuterated chloroform (CDCl3) or dimethyl sulfoxide (DMSO-d6) as 253 
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solvent. Chemical shifts were expressed in parts per million (ppm) relative to 254 
tetramethylsilane and coupling constants (J) values are given in Hertz (Hz). Signal 255 
multiplicities are represented as singlet (s), doublet (d), doublet of doublet (dd), and 256 
multiplet (m). The reaction progress of all compounds was monitored by thin-layer 257 
chromatography (TLC), which was performed on 2.0- by 6.0-cm2 aluminum sheets 258 
precoated with silica gel 60 (HF-254; Merck) to a thickness of 0.25 mm and revealed 259 
under UV light (265 nm). Purification procedures were performed on a chromatography 260 
column with silica gel (60 Å pore size, 35-75-µm particle size) and the following solvents 261 
were used as mobile phase: methanol, ethyl acetate, dichloromethane and hexane.  262 
All compounds were analyzed by HPLC, and their purity was confirmed to be greater 263 
than 98.5%. HPLC conditions: Shimadzu HPLC model CBM 20-A (Shimadzu®) 264 
equipped with UV-VIS detector (model SPD-20A), quaternary pumping system mobile 265 
phase (model LC-20AT), solvent degasser (model DGU-20As) and a Agilent® Eclipse 266 
XDB C-18 column (250mm x 27 4,6mm; 5μm). For HPLC method it was used an 267 
isocratic flow [methanol:water (75:25)]. 268 
Reagents and solvents were purchased from commercial suppliers and used as received. 269 
Isonicotinohydrazide, benzoylacetonitrile 10 and 6-methylbenzofuroxan 7 were 270 
purchased commercially. Compounds 6 and 8 were prepared according to a previously 271 
described methodology [24,15].  272 
 273 
Synthetic route A 274 
General procedure for preparation of compound 3 275 
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Conventional synthesis. Compound 8 (0.3 g; 1.06 mmol) was dissolved in 276 
dichloromethane (15 mL) and then cooled by placing it on ice batch. Next, 277 
benzoylacetonitrile (0.15 g; 1.06 mmol) was added in small portions and K2CO3 (0.18g; 278 
1.32 mmol) was added as base. The reaction mixture was stirred at 40 ºC for 48 hours, 279 
depending on the benzofuroxan derivative used. After the reaction time, the solvent was 280 
evaporated under reduced pressure and the obtained oil or solid was dissolved in 50 mL 281 
of ethyl acetate and washed with water. The organic phase was dried with anhydrous 282 
Na2SO4 and the solvent was evaporated under reduced pressure giving a complex black 283 
oil mixture. The desired compound was not obtained. 284 
Microwave-assisted synthesis. Compound 8 (0.5 g; 1.7 mmol) was dissolved in toluene 285 
(10 mL) in a microwave vessel (35 mL). The mixture was cooled with ice batch. Next, 286 
benzoylacetonitrile (0.25 g; 1.7 mmol) was added in small portions and triethylamine 287 
(0.35 mL; 55 mmol) was added dropwise as base. The reaction mixture was stirred at 288 
room temperature for 15 minutes, and after that, the reaction mixture was inserted in a 289 
microwave synthesizer and then subject to an optimized method: microwave irradiation 290 
at 70 W for 30 minutes, keeping the temperature at 40 ºC. Once the reaction time 291 
finished, the solvent was eliminated under reduced pressure. A black oil was obtained 292 
and it was dissolved in 50 mL of ethyl acetate and washed with water. The organic phase 293 
was dried with anhydrous Na2SO4 and the solvent was evaporated under reduced pressure 294 
giving a black oil. The desired compound was not obtained. 295 
 296 
Synthetic route B 297 
General procedure for preparation of compound 11 298 
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Conventional synthesis. Compound 6 (0.3 g; 1.06 mmol) was dissolved in 299 
dichloromethane (15 mL) and then cooled by placing it on ice batch. Next, 300 
benzoylacetonitrile (0.15 g; 1.06 mmol) was added in small portions and K2CO3 (0.18g; 301 
1.32 mmol) was added as base. The reaction mixture was stirred at 40 ºC for 48 hours, 302 
depending on the benzofuroxan derivative used. After the reaction time, the solvent was 303 
evaporated under reduced pressure and the obtained oil or solid was dissolved in 50 mL 304 
of ethyl acetate and washed with water. The organic phase was dried with anhydrous 305 
Na2SO4 and the solvent was evaporated under reduced pressure giving a complex black 306 
oil mixture. The desired compound was not obtained. 307 
Microwave-assisted synthesis. Compound 6 (0.5 g; 1.7 mmol) was dissolved in toluene 308 
(10 mL) in a microwave vessel (35 mL). The mixture was cooled with ice batch. Next, 309 
benzoylacetonitrile (0.25 g; 1.7 mmol) was added in small portions and triethylamine 310 
(0.35 mL; 55 mmol) was added dropwise as base. The reaction mixture was stirred at 311 
room temperature for 15 minutes, and after that, the reaction mixture was inserted in a 312 
microwave synthesizer and then subject to an optimized method: microwave irradiation 313 
at 70 W for 30 minutes, keeping the temperature at 40 ºC. Once the reaction time 314 
finished, the solvent was eliminated under reduced pressure. A black oil was obtained 315 
and it was dissolved in 50 mL of ethyl acetate and washed with water. The organic phase 316 
was dried with anhydrous Na2SO4 and the solvent was evaporated under reduced pressure 317 
giving a black oil. The desired compound was not obtained. 318 
 319 
Synthetic route C 320 
General procedure for preparation of compound 12 321 
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Conventional synthesis. Compound 7 (0.3 g; 1.06 mmol) was dissolved in 322 
dichloromethane (15 mL) and then cooled by placing it on ice batch. Next, 323 
benzoylacetonitrile (0.15 g; 1.06 mmol) was added in small portions and K2CO3 (0.18g; 324 
1.32 mmol) was added as base. The reaction mixture was stirred at 40 ºC for 48 hours, 325 
depending on the benzofuroxan derivative used. After the reaction time, the solvent was 326 
evaporated under reduced pressure and the obtained solid was dissolved in 50 mL of 327 
ethyl acetate and washed with water. The organic phase was dried with anhydrous 328 
Na2SO4 and the solvent was evaporated under reduced pressure giving a yellow powder. 329 
The obtained yellow solid was purified by silica gel column chromatography using 330 
hexane and ethyl acetate (70:30 v/v) as eluent to give the appropriate compound 12 as a 331 
yellow powder. 332 
Microwave-assisted synthesis. Compound 7 (0.5 g; 1.7 mmol) was dissolved in toluene 333 
(10 mL) in a microwave vessel (35 mL). The mixture was cooled with ice batch. Next, 334 
benzoylacetonitrile (0.25 g; 1.7 mmol) was added in small portions and triethylamine 335 
(0.35 mL; 55 mmol) was added dropwise as base. The reaction mixture was stirred at 336 
room temperature for 15 minutes, and after that, the reaction mixture was inserted in a 337 
microwave synthesizer and then subject to an optimized method: microwave irradiation 338 
at 70 W for 30 minutes, keeping the temperature at 40 ºC. Once the reaction time 339 
finished, the solvent was eliminated under reduced pressure. A black oil or a solid was 340 
obtained and it was dissolved in 50 mL of ethyl acetate and washed with water. The 341 
organic phase was dried with anhydrous Na2SO4 and the solvent was evaporated under 342 
reduced pressure giving a yellow solid. The obtained yellow solid was purified by silica 343 
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gel column chromatography using hexane and ethyl acetate (70:30 v/v) as eluent to give 344 
the appropriate compound 12 as a yellow powder. 345 
 346 
3-cyano-6-methyl-2-phenylquinoxaline 1,4-di-N-oxide (12). Yellow powder; yield, 347 
26%; mp, 188 to 190 °C. IR Vmax (cm-1; KBr pellets): 3065 (C-H aromatic), 2241 (CN 348 
nitrile), 1347 (N-O). 1H NMR (400 MHz, DMSO-d6, δ ppm) δ: 8.58 (1H, m, Ar-H), 8.40 349 
(1H, s, Ar-H), 7.81 (1H, d, J = 2.3 Hz, Ar-H), 7.74 (2H, m, Ar-H), 7.61 (3H, m, Ar-H), 350 
2.67 (3H, s, 13-CH3) ppm. 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 144.9, 136.6, 132.0, 351 
130.4, 129.3, 127.0, 126.9, 121.3 (2C), 120.8, 120.5, 120.0 (2C), 110.5, 22.2 ppm. Anal. 352 
Calcd. (%) for C16H11N3O2: C: 69.31; H: 4.00; N: 15.15. Found: C: 69.54; H: 4.10; N: 353 
15.41. 354 
 355 
General procedure for preparation of compound 11 356 
Conventional synthesis. Compound 12 (0.35 g; 1.26 mmol) and selenium dioxide (0.14 357 
g; 1.26 mmol) were dissolved in ethyl acetate (10 mL). The mixture reaction was stirred 358 
under reflux for 24 hours. No changes in TLC were observed after the reaction time. 359 
Microwave-assisted synthesis. Compound 12 (0.35 g; 1.26 mmol) and selenium dioxide 360 
(0.14 g; 1.26 mmol) were dissolved in ethyl acetate (10 mL) in a microwave vessel (35 361 
mL). The mixture reaction was stirred at room temperature for 15 minutes and then 362 
placed in a microwave reactor. The mixture was then subjected to microwave irradiation 363 
at 200 W for 1 hour at 70 ºC. No changes in TLC were observed after the reaction time. 364 
 365 
Synthetic route D 366 
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General procedure for preparation of compound 9. A mixture of 6 (0.8 g; 4.8 mmol), 367 
ethylene glycol (2 mL; 35 mmol), p-toluenesulfonic acid (0.14 g; 2%) and toluene (15 368 
mL) was stirred under reflux for 12 hours. After the reaction time, the solvent was 369 
eliminated under reduced pressure. The obtained oil was dissolved in 50 mL of 370 
dichloromethane and washed with saturated aqueous NaHCO3, water and brine. The 371 
organic phase was dried with anhydrous Na2SO4 and the solvent was evaporated under 372 
reduced pressure giving a brown solid. The obtained solid was purified by silica gel 373 
column chromatography using hexane and ethyl acetate (70:30 v/v) as eluent to give 374 
compound 9 as a yellow powder. 375 
 376 
6-(1,3-dioxolan-2-yl)benzo[c][1,2,5]oxadiazole 1-oxide (9). Yellow powder; yield, 85%; 377 
mp, 62 to 63 °C. IR Vmax (cm-1; KBr pellets): 3065 (C-H aromatic), 1359 (N-O), 1078 (C-378 
O ether). 1H NMR (400 MHz, CDCl3, δ ppm) δ: 7.47 (3H, m, Ar-H), 5.80 (1H, s, 11-379 
CH), 4.09 (4H, m, 14-CH, 15-CH) ppm. 13C NMR (75 MHz, CDCl3, δ ppm) δ: 102.4, 380 
65.9 (2C) ppm. Anal. Calcd. (%) for C9H8N2O4: C: 51.93; H: 3.87; N: 13.46. Found: C: 381 
52.30; H: 3.91; N: 13.54. 382 
 383 
General procedure for preparation of compound 13 384 
Conventional synthesis. Compound 9 (0.3 g; 1.06 mmol) was dissolved in 385 
dichloromethane (15 mL) and then cooled by placing it on ice batch. Next, 386 
benzoylacetonitrile (0.15 g; 1.06 mmol) was added in small portions and K2CO3 (0.18g; 387 
1.32 mmol) was added as base. The reaction mixture was stirred at 40 ºC for 96 hours, 388 
depending on the benzofuroxan derivative used. After the reaction time, the solvent was 389 
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evaporated under reduced pressure and the obtained solid was dissolved in 50 mL of 390 
ethyl acetate and washed with water. The organic phase was dried with anhydrous 391 
Na2SO4 and the solvent was evaporated under reduced pressure giving a yellow powder. 392 
The obtained yellow solid was purified by silica gel column chromatography using 393 
hexane and ethyl acetate (70:30 v/v) as eluent to give the appropriate compound 13 as a 394 
yellow powder. 395 
Microwave-assisted synthesis. Compound 9 (0.5 g; 1.7 mmol) was dissolved in toluene 396 
(10 mL) in a microwave vessel (35 mL). The mixture was cooled with ice batch. Next, 397 
benzoylacetonitrile (0.25 g; 1.7 mmol) was added in small portions and triethylamine 398 
(0.35 mL; 55 mmol) was added dropwise as base. The reaction mixture was stirred at 399 
room temperature for 15 minutes, and after that, the reaction mixture was inserted in a 400 
microwave synthesizer and then subject to an optimized method: microwave irradiation 401 
at 70 W for 30 minutes, keeping the temperature at 40 ºC. Once the reaction time 402 
finished, the solvent was eliminated under reduced pressure. A black oil or a solid was 403 
obtained and it was dissolved in 50 mL of ethyl acetate and washed with water. The 404 
organic phase was dried with anhydrous Na2SO4 and the solvent was evaporated under 405 
reduced pressure giving a yellow solid. The obtained yellow solid was purified by silica 406 
gel column chromatography using hexane and ethyl acetate (70:30 v/v) as eluent to give 407 
the appropriate compound 13 as a yellow powder. 408 
 409 
3-cyano-6-(1,3-dioxolan-2-yl)-2-phenylquinoxaline 1,4-di-N-oxide (13). Yellow 410 
powder; yield, 30%; mp, 158 to 159 °C. IR Vmax (cm-1; KBr pellets): 3089 (C-H 411 
aromatic), 2235 (CN nitrile), 1335 (N-O), 1098 (C-O ether). 1H NMR (400 MHz, 412 
22 
 
 
DMSO-d6, δ ppm) δ: 8.55 (2H, d, J = 9.1 Hz, Ar-H), 8.11 (1H, dd, J = 28.4 Hz, Ar-H), 413 
7.74 (2H, s, Ar-H), 7.63 (3H, m, Ar-H), 6.10 (1H, s, 11-CH), 4.10 (4H, m, 22-CH, 23-414 
CH) ppm. 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 144.1, 143.0, 139.2, 131.0, 130.6, 415 
130.1 (2C), 128.9, 128.5 (2C), 127.7, 126.9, 121.0, 117.1, 101.0, 65.2 (2C) ppm. Anal. 416 
Calcd. (%) for C18H13N3O4: C: 64.48; H: 3.91; N: 12.53. Found: C: 64.58; H: 4.11; N: 417 
12.82. 418 
 419 
General procedure for preparation of compound 11. Compound 13 (0.2 g; 0.6 mmol) 420 
was dissolved in acetone (15 mL). Next, hydrochloric acid (0.3 mL) was added dropwise. 421 
The reaction mixture was stirred at room temperature for 48 hours. After the reaction 422 
time, the solvent was evaporated under reduced pressure and dissolved in 30 mL of 423 
dichloromethane and washed with saturated aqueous NaHCO3, water and brine. Next, the 424 
solvent was dried with anhydrous Na2SO4 and evaporated under reduced pressure giving 425 
an orange solid 11. The obtained powder was used in the next reaction without further 426 
purification. 427 
 428 
General procedure for preparation of compound 3. Compound 11 (0.15 g; 0.52 429 
mmol) was dissolved in 20 mL of ethanol and then, acetic acid was added dropwise until 430 
the solution reached pH 5. The reaction mixture was stirred for 15 minutes. Next, 431 
isonicotinohydrazide (0.077 g; 0.56 mmol) was added. The reaction mixture was stirred 432 
at room temperature for 12 hours. After the reaction time, an orange solid was 433 
precipitated and it was filtered and washed with cold ethanol.  The obtained orange solid 434 
23 
 
 
was purified by silica gel column chromatography using dichloromethane and methanol 435 
(95:5 v/v) as eluent to give compound 3 as an orange powder. 436 
 437 
(E)-3-cyano-6-((2-isonicotinoylhydrazono)methyl)-2-phenylquinoxaline 1,4-di-N-oxide 438 
(3). Orange powder; yield, 66%; mp, 243 to 244 °C. IR Vmax (cm-1; KBr pellets): 3284 439 
(N-H), 3084 (C-H aromatic), 1702 (C=O amide), 1675 (C=N imine), 1608 (N-N), 1347 440 
(N-O), 1314 (C-N aromatic). 1H NMR (400 MHz, DMSO-d6, δ ppm) δ: 12.52 (1H, s, 441 
NH), 8.81 (3H, d, J = 10.2 Hz, Ar-H), 8.73 (1H, s, 11-CH), 8.60 (1H, t, J = 8.2 Hz, Ar-442 
H), 8.48 (1H, m, Ar-H), 7.86 (2H, m, Ar-H), 7.75 (2H, m, Ar-H), 7.64 (3H, m, Ar-H) 443 
ppm. 13C NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.1, 150.4 (2C), 146.0, 145.9, 139.4, 444 
137.3, 131.1, 130.9, 130.1 (2C), 129.9, 128.6 (2C), 127.6, 125.0, 121.6 (2C), 120.9, 119.1 445 
ppm. Anal. Calcd. (%) for C22H14N6O3: C: 64.39; H: 3.44; N: 20.48. Found: C: 64.58; H: 446 
3.62; N: 20.64. 447 
 448 
Acknowledgments. This study was supported by Fundação de Amparo à Pesquisa do 449 
Estado de São Paulo (FAPESP grants 2014/02240-1; 2014/24811-0). 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
24 
 
 
 458 
 459 
 460 
 461 
462 
25 
 
 
REFERENCES AND NOTES 463 
 464 
[1] Carta, A.; Corona, P.; Loriga, M. Curr Med Chem 2005, 12, 2259. 465 
[2] Suter, W.; Rosselet, A.; Knüsel, F. Antimicrob Agents Chemother 1978, 13, 770. 466 
[3] Ganley, B.; Chowdhury, G.; Bhansali, J.; Daniels, J. S.; Gates, K. S. Bioorg Med 467 
Chem 2001, 9, 2395. 468 
[4] Cheng, G.; Sa, W.; Cao, C.; Guo, L.; Hao, H.; Liu, Z.; Wang, X.; Yuan, Z. Front 469 
Pharmacol 2016, 7, 1. 470 
[5] Villar, R.; Vicente, E.; Solano, B.; Pérez-Silanes, S.; Aldana, I.; Maddry, J. A.; 471 
Lenaerts, A. J.; Franzblau, S. G.; Cho, S. H.; Monge, A.; Goldman, R. C. J 472 
Antimicrob Chemother 2008, 62, 547. 473 
[6] Vicente, E.; Villar, R.; Burguete, A.; Solano, B.; Pérez-Silanes, S.; Aldana, I.; 474 
Maddry, J. A.; Lenaerts, A. J.; Franzblau, S. G.; Cho, S. H.; Monge, A.; Goldman, 475 
R. C. Antimicrob Agents Chemother 2008, 52, 3321. 476 
[7] Ancizu, S.; Moreno, E.; Solano, B.; Villar, R.; Burguete, A.; Torres, E.; Pérez-477 
Silanes, S.; Aldana, I.; Monge, A. Bioorg Med Chem 2010, 18, 2713. 478 
[8] Moreno, E.; Ancizu, S.; Pérez-Silanes, S.; Torres, E.; Aldana, I.; Monge, A. Eur J 479 
Med Chem 2010, 45, 4418. 480 
[9] Vicente, E.; Villar, R.; Pérez-Silanes, S.; Aldana, I.; Goldman, R. C.; Monge, A. 481 
Infect Disord Drug Targets 2011, 11, 196. 482 
[10] Vicente, E.; Pérez-Silanes, S.; Lima, L. M.; Ancizu, S.; Burguete, A.; Solano, B.; 483 
Villar, R.; Aldana, I.; Monge, A. Bioorg Med Chem 2009, 17, 385. 484 
[11] Torres, E.; Moreno, E.; Ancizu, S.; Barea, C.; Galiano, S.; Aldana, I.; Monge, A.; 485 
Pérez-Silanes, S. Bioorg Med Chem Lett 2011, 21, 3699. 486 
[12] Rollas, S.; Küçükgüzel, Ş. G. Molecules 2007, 12, 1910. 487 
[13] Narang, R.; Narasimhan, B.; Sharma, S. Curr Med Chem 2012, 19, 569. 488 
[14] Fernandes, G. F.; Souza, P. C.; Marino, L. B.; Chegaev, K.; Gugliemo, S.; 489 
Lazzarato, L.; Fruttero, R.; Chung, M. C.; Pavan, R. F.; Santos, J. L. Eur J Med 490 
Chem 2016, 123, 523. 491 
[15] Dutra, L. A.; De Almeida, L.; Passalacqua, T. G.; Reis, J. S.; Torres, F. A. E.; 492 
Martinez, I.;  Peccinini, R. G.; Chung, M. C.; Chegaev, K.; Guglielmo, S.; 493 
Fruttero, R.; Graminha, M. A. S.; Santos, J. L. Antimicrob Agents Chemother 494 
2014, 58, 4837. 495 
[16] Pavan, F. R.; Maia, P. I. S.; Leite, S. R. A.; Deflon, V. M.; Batista, A. A.; Sato, D. 496 
N.; Franzblau, S. G.; Leite, C. Q. F. Eur J Med Chem 2010, 45, 1898. 497 
[17] Sriram, D.; Yogeeswari, P.; Devakaram, R. V.; Bioorg Med Chem 2006, 14, 3113. 498 
[18] Haddadin, M. J.; Issidorides, C. H. Tetrahedron Lett 1965, 6, 3253. 499 
[19] Haddadin, M. J.; Issidorides, C. H. Heterocycles 1976, 4, 767. 500 
[20] Issidorides, C. H.; Haddadin, M. J. J Org Chem 1966, 31, 4067. 501 
[21] Lima, L. M.; Amaral, D. N. Rev Virtual Quim 2013, 5, 1075. 502 
[22] Barea, C.; Pabón, A.; Pérez-Silanes, S.; Galiano, S.; Gonzalez, G.; Monge, A.; 503 
Deharo, E.; Aldana, I. Molecules 2013, 18, 4718. 504 
[23] Lidström, P.; Tierney, J.; Wathey, B.; Westman, J. Tetrahedron 2001, 57, 9225. 505 
[24] Ghosh, P. B.; Whitehouse, M. W. J Med Chem 1968, 11, 305. 506 
[25] Wathey, B.; Tierney, J.; Lidstrom, P.; Westman, J. Drug Discovery Today 2002, 7, 507 
26 
 
 
373. 508 
[26] Strauss, C. R.; Trainor, R. W. Aust J Chem 1995, 48, 1665. 509 
[27] Młochowski, J.; Brząszcz, M.; Giurg, M.; Palus, J.; Wójtowicz, H. Eur J Org 510 
Chem 2003, 2003, 4329. 511 
[28] Wuts, P. G. M.; Greene, T. W. Greene's Protective Groups in Organic Synthesis;  512 
Wiley-Interscience: New York, 2006; pp 431–532. 513 
[29] Lima, L. M.; Zarranz, B.; Marin, A.; Solano, B.; Vicente, E.; Perez-Silanes, S.; 514 
Aldana, I.; Monge, A. J Heterocycl Chem 2005, 42, 1381. 515 
[30] Ancizu, S.; Moreno, E.; Torres, E.; Burguete, A.; Pérez-Silanes, S.; Benítez, D.; 516 
Villar, R.; Solano, B.; Marin, A.; Aldana, I.; Cerecetto, H.; Gonzalez, M.; Monge, 517 
A. Molecules 2009, 14, 2256. 518 
[31] Pérez-Silanes, S.; Torres, E.; Arbillaga, L.; Varela, J.; Cerecetto, H.; Gonzalez, M.; 519 
Azqueta, A.; Moreno, E. Bioorg Med Chem Lett 2016, 26, 903. 520 
[32] Vicente, E.; Lima, L. M.; Bongard, E.; Charnaud, S.; Villar, R.; Solano, B.; 521 
Burguete, A.; Pérez-Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Eur J Med Chem 522 
2008, 43, 1903. 523 
  524 
